Improvement of cardiac performance and cardiovascular risk factors in children with GH deficiency after two years of GH replacement therapy: an observational, open, prospective, case-control study

J Clin Endocrinol Metab. 2006 Apr;91(4):1288-95. doi: 10.1210/jc.2005-0981. Epub 2006 Jan 10.

Abstract

Context: GH deficiency (GHD) in adults is associated with a cluster of cardiovascular risk factors that may contribute to an increased mortality for cardiovascular disease.

Objective: The aim of this study was to evaluate the effect of GHD and GH replacement therapy on cardiac performance, lipid profile, and insulin resistance in children.

Design: This was a 2-yr case-control prospective study.

Patients: Thirty children with GHD aged 9.3 +/- 0.5 yr and 30 healthy matched controls were studied.

Intervention: Children were studied before and after 1 and 2 yr of GH replacement (GHD children) or no treatment (controls).

Main outcome measures: Lipid profile, serum insulin levels, homeostasis model of assessment (HOMA) index, and left ventricular (LV) mass and function by echocardiography were the main outcome measures.

Results: At study entry, the LV mass index was significantly lower in GHD children (50.2 +/- 1.7) than in controls (60.3 +/- 2.5 g/m(2); P < 0.002), whereas LV systolic and diastolic function, lipid profile, insulin levels, and HOMA index were similar. In GHD children LV mass index significantly increased (66.3 +/- 2.4 g/m(2); P < 0.0001) after 1 yr of GH replacement and remained stable thereafter. LV systolic and diastolic function did not change during treatment. After 2 yr of GH replacement, total cholesterol (P < 0.007) and the atherogenic index (P < 0.0001) significantly decreased, whereas fasting insulin levels (P < 0.001) and HOMA index (P < 0.0001) significantly increased compared with both pretreatment and control values.

Conclusions: GHD in children is associated with a reduced cardiac size but with a normal cardiac function, lipid profile, and insulin sensitivity. Two years of GH replacement normalizes cardiac morphology, improves lipid profile, and slightly impairs insulin sensitivity.

Publication types

  • Clinical Trial

MeSH terms

  • Cardiovascular Diseases / diagnostic imaging
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / prevention & control*
  • Case-Control Studies
  • Child
  • Echocardiography
  • Female
  • Growth Hormone / therapeutic use*
  • Heart / anatomy & histology
  • Heart / drug effects*
  • Heart Function Tests
  • Human Growth Hormone / blood
  • Human Growth Hormone / deficiency*
  • Humans
  • Lipid Metabolism
  • Male
  • Prospective Studies
  • Risk Factors

Substances

  • Human Growth Hormone
  • Growth Hormone